Cargando…

按需糖皮质激素治疗对再生障碍性贫血p-ALG治疗相关血清病反应发生及转归的影响

OBJECTIVE: To investigate the effect of on-demand glucocorticoid strategy on the occurrence and outcome of porcine anti-lymphocyte globulin (p-ALG)-associated serum sickness in aplastic anemia (AA). METHODS: The data of AA patients who received in the Anemia Diagnosis and Treatment Center of Haemato...

Descripción completa

Detalles Bibliográficos
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Editorial office of Chinese Journal of Hematology 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10119721/
https://www.ncbi.nlm.nih.gov/pubmed/37356982
http://dx.doi.org/10.3760/cma.j.issn.0253-2727.2023.03.006
_version_ 1785029063801307136
collection PubMed
description OBJECTIVE: To investigate the effect of on-demand glucocorticoid strategy on the occurrence and outcome of porcine anti-lymphocyte globulin (p-ALG)-associated serum sickness in aplastic anemia (AA). METHODS: The data of AA patients who received in the Anemia Diagnosis and Treatment Center of Haematology Hospital, CAMS & PUMC from January 2019 to January 2022 were collected. Among them, 35 patients were enrolled in the on-demand group, with the glucocorticoid strategy adjusted based on the occurrence and severity of serum sickness; 105 patients were recruited in the usual group by matching the age and disease diagnosis according to 1∶3 ratio in patients who received a conventional glucocorticoid strategy in the same period. The incidences, clinical manifestations, treatment outcomes of serum sickness, and glucocorticoid dosage between the two groups were analyzed. RESULTS: The incidences of serum sickness in the on-demand group and the usual group were 65.7% and 54.3% (P=0.237), respectively. The median onset of serum sickness was the same [12 (9, 13) d vs the 12 (10, 13) d, P=0.552], and clinical symptoms and signs, primarily joint, and/or muscle pain, fever, and rash were similar. Severity grades were both dominated by Grades 1–2 (62.8% vs 51.4%), with only a few Grade 3 (2.9% vs 2.9%), and no Grades 4–5. No significant difference in the serum sickness distribution (P=0.530). The median duration of serum sickness was the same [5 (3, 7) d vs 5 (3, 6) d, P=0.529], and all patients were completely cured after glucocorticoid therapy. In patients without serum sickness, the average dosage of prophylactic glucocorticoid per patient in the usual group was (469.48 ±193.57) mg (0 in the on-demand group). When compared to the usual group, the average therapeutic glucocorticoid dosage per patient in the on-demand group was significantly lower [(125.91±77.70) mg vs (653.90±285.56) mg, P<0.001]. CONCLUSION: In comparison to the usual glucocorticoid strategy, the on-demand treatment strategy could significantly reduce glucocorticoid dosage without increasing the incidence of serum sickness; in addition, the duration of serum sickness and the incidence of above Grade 2-serum sickness were similar.
format Online
Article
Text
id pubmed-10119721
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher Editorial office of Chinese Journal of Hematology
record_format MEDLINE/PubMed
spelling pubmed-101197212023-04-22 按需糖皮质激素治疗对再生障碍性贫血p-ALG治疗相关血清病反应发生及转归的影响 Zhonghua Xue Ye Xue Za Zhi 论著 OBJECTIVE: To investigate the effect of on-demand glucocorticoid strategy on the occurrence and outcome of porcine anti-lymphocyte globulin (p-ALG)-associated serum sickness in aplastic anemia (AA). METHODS: The data of AA patients who received in the Anemia Diagnosis and Treatment Center of Haematology Hospital, CAMS & PUMC from January 2019 to January 2022 were collected. Among them, 35 patients were enrolled in the on-demand group, with the glucocorticoid strategy adjusted based on the occurrence and severity of serum sickness; 105 patients were recruited in the usual group by matching the age and disease diagnosis according to 1∶3 ratio in patients who received a conventional glucocorticoid strategy in the same period. The incidences, clinical manifestations, treatment outcomes of serum sickness, and glucocorticoid dosage between the two groups were analyzed. RESULTS: The incidences of serum sickness in the on-demand group and the usual group were 65.7% and 54.3% (P=0.237), respectively. The median onset of serum sickness was the same [12 (9, 13) d vs the 12 (10, 13) d, P=0.552], and clinical symptoms and signs, primarily joint, and/or muscle pain, fever, and rash were similar. Severity grades were both dominated by Grades 1–2 (62.8% vs 51.4%), with only a few Grade 3 (2.9% vs 2.9%), and no Grades 4–5. No significant difference in the serum sickness distribution (P=0.530). The median duration of serum sickness was the same [5 (3, 7) d vs 5 (3, 6) d, P=0.529], and all patients were completely cured after glucocorticoid therapy. In patients without serum sickness, the average dosage of prophylactic glucocorticoid per patient in the usual group was (469.48 ±193.57) mg (0 in the on-demand group). When compared to the usual group, the average therapeutic glucocorticoid dosage per patient in the on-demand group was significantly lower [(125.91±77.70) mg vs (653.90±285.56) mg, P<0.001]. CONCLUSION: In comparison to the usual glucocorticoid strategy, the on-demand treatment strategy could significantly reduce glucocorticoid dosage without increasing the incidence of serum sickness; in addition, the duration of serum sickness and the incidence of above Grade 2-serum sickness were similar. Editorial office of Chinese Journal of Hematology 2023-03 /pmc/articles/PMC10119721/ /pubmed/37356982 http://dx.doi.org/10.3760/cma.j.issn.0253-2727.2023.03.006 Text en 2023年版权归中华医学会所有 https://creativecommons.org/licenses/by/3.0/This work is licensed under a Creative Commons Attribution 3.0 License.
spellingShingle 论著
按需糖皮质激素治疗对再生障碍性贫血p-ALG治疗相关血清病反应发生及转归的影响
title 按需糖皮质激素治疗对再生障碍性贫血p-ALG治疗相关血清病反应发生及转归的影响
title_full 按需糖皮质激素治疗对再生障碍性贫血p-ALG治疗相关血清病反应发生及转归的影响
title_fullStr 按需糖皮质激素治疗对再生障碍性贫血p-ALG治疗相关血清病反应发生及转归的影响
title_full_unstemmed 按需糖皮质激素治疗对再生障碍性贫血p-ALG治疗相关血清病反应发生及转归的影响
title_short 按需糖皮质激素治疗对再生障碍性贫血p-ALG治疗相关血清病反应发生及转归的影响
title_sort 按需糖皮质激素治疗对再生障碍性贫血p-alg治疗相关血清病反应发生及转归的影响
topic 论著
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10119721/
https://www.ncbi.nlm.nih.gov/pubmed/37356982
http://dx.doi.org/10.3760/cma.j.issn.0253-2727.2023.03.006
work_keys_str_mv AT ànxūtángpízhìjīsùzhìliáoduìzàishēngzhàngàixìngpínxuèpalgzhìliáoxiāngguānxuèqīngbìngfǎnyīngfāshēngjízhuǎnguīdeyǐngxiǎng
AT ànxūtángpízhìjīsùzhìliáoduìzàishēngzhàngàixìngpínxuèpalgzhìliáoxiāngguānxuèqīngbìngfǎnyīngfāshēngjízhuǎnguīdeyǐngxiǎng
AT ànxūtángpízhìjīsùzhìliáoduìzàishēngzhàngàixìngpínxuèpalgzhìliáoxiāngguānxuèqīngbìngfǎnyīngfāshēngjízhuǎnguīdeyǐngxiǎng
AT ànxūtángpízhìjīsùzhìliáoduìzàishēngzhàngàixìngpínxuèpalgzhìliáoxiāngguānxuèqīngbìngfǎnyīngfāshēngjízhuǎnguīdeyǐngxiǎng
AT ànxūtángpízhìjīsùzhìliáoduìzàishēngzhàngàixìngpínxuèpalgzhìliáoxiāngguānxuèqīngbìngfǎnyīngfāshēngjízhuǎnguīdeyǐngxiǎng
AT ànxūtángpízhìjīsùzhìliáoduìzàishēngzhàngàixìngpínxuèpalgzhìliáoxiāngguānxuèqīngbìngfǎnyīngfāshēngjízhuǎnguīdeyǐngxiǎng
AT ànxūtángpízhìjīsùzhìliáoduìzàishēngzhàngàixìngpínxuèpalgzhìliáoxiāngguānxuèqīngbìngfǎnyīngfāshēngjízhuǎnguīdeyǐngxiǎng
AT ànxūtángpízhìjīsùzhìliáoduìzàishēngzhàngàixìngpínxuèpalgzhìliáoxiāngguānxuèqīngbìngfǎnyīngfāshēngjízhuǎnguīdeyǐngxiǎng
AT ànxūtángpízhìjīsùzhìliáoduìzàishēngzhàngàixìngpínxuèpalgzhìliáoxiāngguānxuèqīngbìngfǎnyīngfāshēngjízhuǎnguīdeyǐngxiǎng
AT ànxūtángpízhìjīsùzhìliáoduìzàishēngzhàngàixìngpínxuèpalgzhìliáoxiāngguānxuèqīngbìngfǎnyīngfāshēngjízhuǎnguīdeyǐngxiǎng
AT ànxūtángpízhìjīsùzhìliáoduìzàishēngzhàngàixìngpínxuèpalgzhìliáoxiāngguānxuèqīngbìngfǎnyīngfāshēngjízhuǎnguīdeyǐngxiǎng
AT ànxūtángpízhìjīsùzhìliáoduìzàishēngzhàngàixìngpínxuèpalgzhìliáoxiāngguānxuèqīngbìngfǎnyīngfāshēngjízhuǎnguīdeyǐngxiǎng
AT ànxūtángpízhìjīsùzhìliáoduìzàishēngzhàngàixìngpínxuèpalgzhìliáoxiāngguānxuèqīngbìngfǎnyīngfāshēngjízhuǎnguīdeyǐngxiǎng
AT ànxūtángpízhìjīsùzhìliáoduìzàishēngzhàngàixìngpínxuèpalgzhìliáoxiāngguānxuèqīngbìngfǎnyīngfāshēngjízhuǎnguīdeyǐngxiǎng
AT ànxūtángpízhìjīsùzhìliáoduìzàishēngzhàngàixìngpínxuèpalgzhìliáoxiāngguānxuèqīngbìngfǎnyīngfāshēngjízhuǎnguīdeyǐngxiǎng